Cargando…

Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission—Niger Experience

BACKGROUND: Outbreaks of vaccine-derived poliovirus type 2 (VDPV2) continue to expand across Africa. We conducted a serological survey of polio antibodies in high–polio risk areas of Niger to assess risk of poliovirus outbreaks. METHODS: Children between 1 and 5 years of age were enrolled from struc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ousmane, Sani, Ibrahim, Dan Dano, Goel, Ajay, Hendley, William S, Mainou, Bernardo A, Palmer, Tess, Diaha, Aissata, Greene, Sharon A, Mach, Ondrej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291560/ https://www.ncbi.nlm.nih.gov/pubmed/34295940 http://dx.doi.org/10.1093/ofid/ofab210

Ejemplares similares

Community-based survey to assess seroprevalence of poliovirus antibodies in far-north Cameroon in 2020
por: Claire Endegue, Marie, et al.
Publicado: (2022)

A Survey to Assess Serological Prevalence of Poliovirus Antibodies in Areas With High-Risk for Vaccine-Derived Poliovirus Transmission in Chad
por: Gamougam, Kadidja, et al.
Publicado: (2021)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh( )
por: Aziz, Asma B, et al.
Publicado: (2022)

Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey
por: Kennedy, Stephen B, et al.
Publicado: (2023)

Inactivated Poliovirus Vaccine Closing the Type 2 Immunity Gap in Vietnam
por: Huyen, Dang Thi Thanh, et al.
Publicado: (2022)

Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey
por: Trueba, Gabriel, et al.
Publicado: (2022)

Achieving high seroprevalence against polioviruses in Sri Lanka-Results from a serological survey, 2014
por: Gamage, Deepa, et al.
Publicado: (2015)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria
por: Iliyasu, Zubairu, et al.
Publicado: (2016)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks()
por: Estivariz, Concepcion F., et al.
Publicado: (2023)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020
por: Alleman, Mary M., et al.
Publicado: (2020)

Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017
por: Diop, Ousmane M., et al.
Publicado: (2017)

Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018–2019
por: Zhao, Hehe, et al.
Publicado: (2021)

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria
por: Verma, Harish, et al.
Publicado: (2018)

Characterizing Environmental Surveillance Sites in Nigeria and Their Sensitivity to Detect Poliovirus and Other Enteroviruses
por: Hamisu, Abdullahi Walla, et al.
Publicado: (2020)

Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010
por: Wallace, Gregory S., et al.
Publicado: (2016)

Assessment of seroprevalence against poliovirus among Italian adolescents and adults
por: Lupi, Silvia, et al.
Publicado: (2018)

Direct detection of polioviruses using a recombinant poliovirus receptor
por: Gerloff, Nancy, et al.
Publicado: (2021)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
por: Jia, Siyue, et al.
Publicado: (2020)

Contribution of Contact Sampling in Increasing Sensitivity of Poliovirus Detection During A Polio Outbreak—Somalia, 2013
por: Moturi, Edna, et al.
Publicado: (2016)

The Origins and Risk Factors for Serotype-2 Vaccine-Derived Poliovirus Emergences in Africa During 2016–2019
por: Gray, Elizabeth J, et al.
Publicado: (2023)

Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses — Worldwide, July 2018–December 2019
por: Macklin, Grace, et al.
Publicado: (2020)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Mucosal immunity to poliovirus
por: Connor, Ruth I., et al.
Publicado: (2021)

Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model
por: Collett, Marc S., et al.
Publicado: (2017)

Seroprevalence rate of Poliovirus antibodies among the Healthy and Protein Energy Malnutrition children
por: Yousuf, Aliya, et al.
Publicado: (2015)

Impact of COVID-19 Pandemic on Global Poliovirus Surveillance
por: Zomahoun, Delayo J., et al.
Publicado: (2021)

Group effort from poliovirus
por: Wells, William A.
Publicado: (2006)

Revealing the Poliovirus’s Path to Infection
por: Gross, Liza
Publicado: (2007)

The Case for Live Poliovirus Vaccination
por: Paul, John R.
Publicado: (1960)

Molecular aspects of poliovirus pathogenesis
por: Nomoto, Akio
Publicado: (2007)

Comparative epidemiology of poliovirus transmission
por: Noori, Navideh, et al.
Publicado: (2017)

The mechanism of RNA recombination in poliovirus
por: Kirkegaard, Karla, et al.
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_0sfo6paou3gmlj9qn7fqk91qit